The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy.

作者: RA Asherson , C Frances , Luca Iaccarino , MA Khamashta , F Malacarne

DOI:

关键词:

摘要: Antiphospholipid antibody syndrome is characterized by venous and/or arterial thrombosis pregnancy morbidity associated with antiphospholipid antibodies (aPL), such as anticardiolipin antibodies, anti beta 2 glycoprotein I and positive lupus anticoagulant test. This may potentially affects any organ system including the skin. Livedo reticularis most frequently observed cutaneous lesion; other lesions, order of frequency, are ulcerations, digital gangrene, subungueal splinter hemorrhages, superficial thrombosis, thrombocytopenic purpura, pseudovasculitic manifestations, extensive necrosis primary anetoderma. Skin lesions more in catastrophic syndrome, widespread microvascular occlusions involving multiple organs simultaneously. Patients should receive long-term oral anticoagulants. The intensity anticoagulation be guided according to nature thrombotic event (venous vs. thrombosis). aPL-associated treated aspirin plus heparin closely monitored during pregnancy. treatment remains unsatisfactory. High dose intravenous steroids parenteral supplemented gammaglobulin repeated plasma exchanges using fresh frozen early on course syndrome.

参考文章(29)
Flavio Allegri, Marielle Sanmarco, Massimo Cinquini, Marco Taglietti, Genesio Balestrieri, Takao Koike, Kenji Ichikawa, Pierluigi Meroni, Marie Claire Boffa, Angela Tincani, Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations--a cooperative project of the European Antiphospholipid Forum. Thrombosis and Haemostasis. ,vol. 86, pp. 575- 583 ,(2001) , 10.1055/S-0037-1616089
Agnes Sparsa, Jean Charles Piette, Bertrand Wechsler, Zahir Amoura, Camille Francès, Anetoderma and its prothrombotic abnormalities. Journal of The American Academy of Dermatology. ,vol. 49, pp. 1008- 1012 ,(2003) , 10.1016/S0190-9622(03)02110-8
Michael H. Rosove, Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients Annals of Internal Medicine. ,vol. 117, pp. 303- 308 ,(1992) , 10.7326/0003-4819-117-4-303
Martial Koenig, Michel Roy, Sylviane Baccot, Muriel Cuilleron, Jean-Pierre de Filippis, Pascal Cath�bras1, Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clinical Rheumatology. ,vol. 24, pp. 166- 168 ,(2005) , 10.1007/S10067-004-1017-1
R A Asherson, The catastrophic antiphospholipid syndrome. The Journal of Rheumatology. ,vol. 19, pp. 508- 512 ,(1992) , 10.1007/978-3-319-11044-8_20
M. Petri, Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scandinavian Journal of Rheumatology. ,vol. 25, pp. 191- 193 ,(1996) , 10.3109/03009749609069986
Munther A Khamashta, Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. Journal of Autoimmunity. ,vol. 15, pp. 249- 253 ,(2000) , 10.1006/JAUT.2000.0421
Silvia S. Pierangeli, Guillermina Girardi, Mariano Vega-Ostertag, Xiaowei Liu, Ricardo G. Espinola, Jane Salmon, Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis & Rheumatism. ,vol. 52, pp. 2120- 2124 ,(2005) , 10.1002/ART.21157
G. FINAZZI, R. MARCHIOLI, V. BRANCACCIO, P. SCHINCO, F. WISLOFF, J. MUSIAL, F. BAUDO, M. BERRETTINI, S. Testa, A. D'ANGELO, G. TOGNONI, T. BARBUI, A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis. ,vol. 3, pp. 848- 853 ,(2005) , 10.1111/J.1538-7836.2005.01340.X